Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5588039 | 0.77 | GABRA1 (0.48) | GABRA1GABRB2ALOX15ALOX12GABRB1 | |
| SCHEMBL5588612 | 0.76 | GABRA1 (0.44) | GABRA1GABRB2ALOX15ALOX12HSP90AA1 | |
| SCHEMBL5588405 | 0.75 | GABRA1 (0.47) | GABRA1GABRB2ALOX15ALOX12ELANE | |
| SCHEMBL11024213 | 0.75 | GABRA1 (0.59) | GABRA1GABRB2ALOX15ALOX12 | |
| SCHEMBL5589644 | 0.75 | GABRA1 (0.36) | GABRA1GABRB2ALOX15ALOX12HSP90AA1 | |
| SCHEMBL24133915 | 0.73 | GABRA1 (0.50) | GABRA1GABRB2ELANECTSG | |
| SCHEMBL23434808 | 0.73 | GABRA1 (0.45) | GABRA1GABRB2ALOX15ALOX12 | |
| SCHEMBL17187961 | 0.73 | GABRA1 (0.60) | GABRA1GABRB2ALOX15ALOX12ELANE | |
| SCHEMBL5587185 | 0.72 | GABRA1 (0.73) | GABRA1GABRB2ELANECTSGGABRB1 | |
| SCHEMBL14167162 | 0.72 | GABRA1 (0.61) | GABRA1GABRB2ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | GABRA1 3688/4885GABRB2 3686/4885ALOX15 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.